Skip to main content

U.S. v. Glenmark Pharmaceuticals Inc., USA


Glenmark Pharmaceuticals Inc., USA is charged with knowingly entering into and engaging in a conspiracy to suppress and eliminate competition by agreeing to increase and maintain prices of pravastatin and other generic drugs sold in the United States. The charged conspiracy began at least as early as May 2013 and continued at least until December 2015.

For further information:

For questions about upcoming public hearings or victims’ rights, contact the Victim Hearing Coordinator in the Washington Criminal I Section.

Case Documents:

Stipulated Protective Order (September 29, 2020)

Second Superseding Indictment (August 25, 2020)

Superseding Indictment (July 14, 2020)

Information (June 30, 2020)

Case Open Date
Case Name
United States v. Glenmark Pharmaceuticals Inc., USA
Case Type
Case Violation(s)
  • Price Fixing - Horizontal
  • Pharmaceuticals
  • Generic Drugs
  • Pravastatin
  • Glenmark Pharmaceuticals
  • Inc.
  • USA
Industry Code(s)
  • Pharmaceutical and Medicine Manufacturing
Updated October 15, 2020